Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Sofia Heigis presents at Redeye Commercialization in Life Science event on March 20

Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.

See the link to Redeye

Oncopeptalks on the company's rights issue

Oncopeptides carries out a rights issue

Oncopeptides AB recently announced that the Board of Directors has decided to carry out a fully guaranteed new share issue of approximately SEK 300 million with preferential rights for the company’s existing ordinary shareholders. Q&A updated March 15.

See Oncopeptalks, Q&A for investors and link to the recorded webcast

Company news

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

February 23, 2024

Oncopeptides AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed.

Read more

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority

February 23, 2024

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti.

Read more

Oncopeptides ensures five years extended market exclusivity for Pepaxti in Europe

February 15, 2024

Oncopeptides AB today announces that it will receive an extension of a key patent ensuring market exclusivity for melflufen, marketed in Europe as Pepaxti, in Europe until 2037, an extension of five years.

Read more

Science news

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

March 1, 2024

Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.

Read more

Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

February 29, 2024

Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.

Read more

Type IB variation process finalized – original indication remains with peripheral administration included

February 7, 2024

Oncopeptides recently received a favorable opinion from EMA to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.

Read more

Investor news

Sofia Heigis presents at Redeye Commercialization in Life Science event on March 20

March 18, 2024

Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.

Read more
Oncopeptalks on the company's rights issue

Oncopeptalks on the company's rights issue

March 13, 2024

Listen to why Oncopeptides is carrying out a new share issue, where the money will go, what a rights issue really is and what you as a current or potential shareholder should think about.

Read more

Sofia Heigis presented at Stora Aktiedagarna in Stockholm

March 6, 2024

Sofia Heigis presented Oncopeptides on Tuesday at Stora Aktiedagarna in Stockholm. During her presentation, followed by a question and answer session, Sofia gave an update on the company, focusing on the changing treatment landscape for melflufen and commercialization in Europe. See the recorded presentation (in Swedish).

Read more
CEO Sofia Heigis - Oncopeptides AB

Released February 27, 2024

Oncopeptides publishes year-end report 2023

Read report

Download

“The fourth quarter sets the stage for revenue acceleration in 2024”

CEO Sofia Heigis

 

See the Webcast

Webcast presentation as pdf

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Q1 interim report 2024 will be published May 30, 2024

Upcoming events

2024-04-15

Extraordinary General Meeting

Meeting

2024-04-22

Annual report 2023

Report

2024-04-29 - 2024-05-29

Silent Period

Other

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Oncopeptides via e-mail